News

The company’s sBLA is supported by the results of a Phase 3 Study (‘147) investigating XGEVA versus placebo in 1,432 men with castrate-resistant prostate cancer. The results of

RP101, a first-in-class small molecule addressing chemo resistance in human cancers with initial focus on pancreatic carcinoma, is to be given in a combination with chemotherapy. Recently, RP101

The agreement allows the commercial partner to continue its research cooperation with Dyadic Netherlands, the R&D subsidiary of Dyadic. Additionally, it will use Dyadic’s patented and proprietary C1

Hsp90 is a member of the heat shock protein family which assists in protein folding, cell signaling, and tumor repression and is a novel target for oncology and

The FDA’s decision follows a Pre-Approval Inspection (PAI) which was done in April 2011 by the US regulators. The company expects to do the filling and packaging of

Teva intends to team up with another two Israeli clinical centers for conducting the study (immunotherapy Multikine anti tumor treatments (IT-MATTERS)), which is already ongoing at several clinical

Watson has acquired the progesterone gel from Columbia in July last year. The product helps to reduce the risk of preterm birth in women with short cervical length.

The research which was conducted by Jun Yan of University of Louisville School of Medicine in Louisville, Kentucky supports another study that found that differences in yeast-derived beta-glucan

MPV offers a suite of patient and payer management solutions that help physician practices and hospitals improve collections, minimize denied claims and accelerate reimbursement. MPV through a combination